(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Positive Pre-Market Momentum for Quhuo, Lyra Therapeutics and Marinus Pharmaceuticals

  • May 26th, 2023
  • 89 views

Quhuo Limited (Nasdaq: QH) announced remarkable achievements in its homestay sector operated by Chengtu Home during the Labor Day holiday. 

According to Quhuo, they recorded an impressive average daily occupancy rate of 95%, representing a significant year-on-year growth of 265% and surpassing RMB12 million in sales revenue. Quhuo's Chairman and CEO, Leslie Yu, expressed satisfaction with Chengtu's vacation rentals, highlighting their value in localized life services. 

Moving forward, Chengtu plans to invest more in lean operational management and innovate its business models to adapt to the evolving tourism sector and meet diverse client demands. 

In pre-market, $QH is experiencing a positive trend, with an increase of $0.60 (+35.71%), currently trading at $2.28.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) has entered into a securities purchase agreement for a private placement that is expected to generate gross proceeds of approximately $50.0 million, subject to customary closing conditions. 

$LYRA is showing a positive trend in pre-market, with a rise of $0.47 (+19.34%), currently trading at $2.90.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of ZTALMY (ganaxolone) oral suspension. This recommendation is for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two to 17 years. ZTALMY may also be continued for patients 18 years and older. 

CDD is a rare genetic disorder characterized by severe neuro-developmental impairment and early-onset, difficult-to-control seizures. 

In pre-market, $MRNS is exhibiting a slight increment of $0.13 (+1.85%), currently trading at $7.16.

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments